口服铁剂类药物联合饮食疗法治疗孕产妇贫血的临床价值研究

Clinical Value of Oral Iron Drugs Combined with Diet Therapy in the Treatment of Maternal Anemia

目的:探讨口服铁剂类药物联合饮食疗法治疗孕产妇贫血的临床价值,以供参考。方法:将牡丹江医学院2011年5月—2013年4月收治的贫血孕产妇105例纳入本研究,随机分组。对照组孕产妇给予口服铁剂类药物治疗,实验组孕产妇给予口服铁剂类药物联合饮食疗法治疗。观察两组孕产妇在治疗前后血红蛋白(Hb)、红细胞计数(RBC)、平均血红蛋白浓度(McHc)、血清铁(SI)、转铁蛋白饱和度(TS)等指标的变化和妊娠结局的差异性。结果:与治疗前对比,治疗后孕产妇Hb、RBC、McHc、SI、TS等指标均有一定程度的上升,其中实验组各指标上升幅度明显大于对照组,组间差异经统计学分析后认为有意义(P<0.05)。与对照组对比,实验组不良妊娠结局发生率明显较低,组间差异统计学分析后认为有意义(P<0.05)。结论:口服铁剂类药物联合饮食疗法治疗孕产妇贫血可有效改善贫血症状,对妊娠结局具有积极的影响。

[Objective] To investigate the clinical value of oral iron drugs combined with diet therapy in the treatment of maternal anemia as reference. [Method] Totally 105 cases of maternal anemia in Hongqi Hospital from May 2011 to April 2013 were enrolled in the study with randomly grouped. Control group was given oral iron therapy, while experimental group was given oral iron drugs combined with diet therapy. The two groups were observed before and after treatment in changes of hemoglobin （Hb）, red blood cell count （RBC）, mean corpuscular hemoglobin concentration （ McHc）, serum iron （ SI）, transferrin saturation （TS） and other indicators and pregnancy outcomes. [Result] Compared with indexes before treatment, Hb, RBC, McHc, SI, TS and other indicators rose after treatment, the experimental group had a significantly greater than the control group, the difference between groups were statistically significant （ P 〈0. 05 ）. Compared with the control group, the adverse pregnancy outcomes of experimental group were significantly lower, differences between the two groups were significant （P 〈 0. 05 ）. [Conclusion] Oral iron drugs combined with diet therapy in the treatment of maternal anemia could effectively improve the symptoms of anemia, and had positive influence on the outcome of pregnancy.